Compare Eli Lilly And Co (LLY) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Wendys Co — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Wendys Co trades at $6.22 (market cap $1.19B). The key difference: Eli Lilly And Co is far larger — about 873.9× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Wendys Co for 77 Days on average.
| LLY | WEN | |
|---|---|---|
Market Cap | $1.04T | $1.19B |
Volume | 3,064,878 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $9.33 |
52-Week Low | $799.57 | $6.10 |
Typical Hold Time | 93 Days | 77 Days |
Enterprise Value | $1.09T | $4.92B |
Dividend Yield | 0.59% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Wendy's (WEN) trades at $6.16, down 71% over five years, with a bearish technical signal and recent price near multi-year lows. The company faces declining same-store sales, a major franchisee bankruptcy (Meritage Hospitality, September 2026), and net income margin compression from 7.58% in 2025 to 5.72% in 2026. Valuation appears low with a P/E of 9.45 and P/S of 0.54, but high debt and operational challenges weigh on sentiment. Recent earnings beats provide some positive momentum, but competitive pressures persist.
The outlook remains cautious due to franchisee instability and sales declines. Investment opportunity lies in potential turnaround under new CEO Bob Wright and cheap valuation, but risks include further store closures, debt burden, and intense burger chain competition. Analyst consensus is mixed with a $7.58 price target, but 65% hold ratings reflect uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
